Navigation Links
Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
Date:2/1/2017

LINCOLN, Mass., Jan. 31, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced that it will collaborate with CytomX Therapeutics (www.cytomx.com) to develop a quantitative systems pharmacology (QSP) model of CytomX Therapeutics' Probody platform.

"We chose Applied BioMath for this project because their past work with us has proven that they are the leader in applying QSP approaches in drug development. We look forward to this collaboration to help us maximize the efficiency of our probody platform for immuno-oncology. "

Michael Kavanaugh, MD, Chief Scientific Officer of CytomX Therapeutics

CytomX Therapeutics' novel Probody Platform allows the design of drugs that take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody while reducing drug activity in healthy tissue.  Applied BioMath's QSP platform model will be systematically studied to better understand how avidity and target expression affect tissue targeting. This model will also be used to predict optimal drug properties and to help understand how to optimize probody efficiencies to maximize anti-tumor targeting while minimizing the normal tissue binding.

"The Probody platform from CytomX Therapeutics is exemplary of the novel approaches needed to transform drug development. We are thrilled to help maximize the efficiency of their innovations leveraging our own proprietary technologies. "

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.  Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.  Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press Contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-and-cytomx-therapeutics-inc-announce-a-collaboration-to-develop-a-quantitative-systems-pharmacology-probody-platform-model-for-use-in-lmmuno-oncology-300399748.html


'/>"/>
SOURCE Applied BioMath
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
2. Applied BioMath, LLC to present at Boston Area Group for Informatics and Modeling Meeting
3. Applied Biophysics Engages ibidi USA as Manufacturer’s Representative in the US and Canada
4. Pittcon Solicits Call for Nominations for 2017 Awards in Areas of Analytical Chemistry and Applied Spectroscopy
5. Applied BioPhysics Introduces pFlow Peristaltic Pump
6. Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board
7. Applied BioMath, LLC. To Sponsor and Present at QSP Congress Boston 2015
8. Pittcon Recognizes Achievements in Analytical Chemistry and Applied Spectroscopy
9. Applied Silicone Launches Silicone Gel System with Dual Matrix Technology
10. Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014
11. Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/5/2017)... , April 5, 2017 Today ... announcing that the server component of the HYPR platform ... for providing the end-to-end security architecture that empowers biometric ... HYPR has already secured over 15 million users ... including manufacturers of connected home product suites and physical ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
Breaking Biology News(10 mins):